| 1 |
Sáez-Briones P, Palma B, Burgos H, Barra R, Hernández A. Aromatic Bromination Abolishes Deficits in Visuospatial Learning Induced by MDMA ("Ecstasy") in Rats While Preserving the Ability to Increase LTP in the Prefrontal Cortex. Int J Mol Sci 2023;24. [PMID: 36835133 DOI: 10.3390/ijms24043724] [Reference Citation Analysis]
|
| 2 |
Boucherie D, Reneman L, Booij J, Martins D, Dipasquale O, Schrantee A. Modulation of functional networks related to the serotonin neurotransmitter system by citalopram: evidence from a multimodal neuroimaging study.. [DOI: 10.1101/2022.10.20.512503] [Reference Citation Analysis]
|
| 3 |
Price CM, Feduccia AA, DeBonis K. Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance. J Clin Psychopharmacol 2022;42:464-9. [PMID: 36018231 DOI: 10.1097/JCP.0000000000001595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 4 |
Vizeli P, Straumann I, Duthaler U, Varghese N, Eckert A, Paulus MP, Risbrough V, Liechti ME. Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects. Front Pharmacol 2022;13:906639. [PMID: 35910354 DOI: 10.3389/fphar.2022.906639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Han M, Liu S, Zhang D, Zhang R, Liu D, Xing H, Sun D, Gong L, Cai P, Tu W, Chen J, Hu QN. AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification. Molecules 2022;27:3931. [PMID: 35745053 DOI: 10.3390/molecules27123931] [Reference Citation Analysis]
|
| 6 |
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl) 2022;239:1945-76. [PMID: 35253070 DOI: 10.1007/s00213-022-06083-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 7 |
Glavonic E, Mitic M, Adzic M. Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. J Neurosci Res 2022. [PMID: 35165930 DOI: 10.1002/jnr.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Okano L, Jones G, Deyo B, Brandenburg A, Hale W. Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder. Front Psychiatry 2022;13:965641. [PMID: 36405928 DOI: 10.3389/fpsyt.2022.965641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Sottile RJ, Vida T. A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. Front Psychiatry 2022;13:991753. [PMID: 36311515 DOI: 10.3389/fpsyt.2022.991753] [Reference Citation Analysis]
|
| 10 |
López-Arnau R, Camarasa J, Carbó ML, Nadal-Gratacós N, Puigseslloses P, Espinosa-Velasco M, Urquizu E, Escubedo E, Pubill D. 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Front Psychiatry 2022;13:990405. [PMID: 36262632 DOI: 10.3389/fpsyt.2022.990405] [Reference Citation Analysis]
|
| 11 |
Young AH. Equasy revisited. J Psychopharmacol 2021;35:499-500. [PMID: 33938311 DOI: 10.1177/02698811211012604] [Reference Citation Analysis]
|
